Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNA-318 in healthy volunteers
NCT06721091Phase 1Completed
- Sponsor
- Vandria SA
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VNA-318 (4 arms), sponsored by Vandria SA. Primary endpoints: Safety and tolerability of single dose and Safety and tolerability of multiple dose. Started Dec 2024; status: completed.
02
Drugs
VNA-318
Beyond the preview
Go deeper on NCT06721091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721091.